直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

Article

Innovation Liberation

September 2020

Intellectual Property Magazine

By Linda J. Thayer

Despite Covid-19, patent filings during the first three months of the pandemic actually increased in the US.1 But if your company hit the pause button on patenting, how do you catch up?

Provisional Patent Applications

Passing the America Invents Act (AIA) in 2013, the US joined the rest of the world in the race to patent. Even during a pandemic, the applicant that files first will receive priority over all others. No special pandemic rules change this. If you or your company cannot afford full application drafting and filing costs now, filing a provisional application for $280 ($140 for small entities), often with existing internal documents drafted by your own engineers, allows you to stake out your place in line and provides you with a one-year grace period to continue innovating, analysing the market, and developing a worldwide patenting strategy before committing larger sums of money. Well-written provisional applications may attract investors and funding while protecting your ownership in your ideas. Consulting a patent attorney or agent at some point before filing is recommended.

Read the full article here. 

Tags

COVID-19

Downloadable Files

  • PUBLISHED - Intellectual Property Magazine - Innovation Liberati

Related Practices

Patent Drafting and Prosecution

Related Offices

Boston, MA

Originally printed in Intellectual Property Magazine in the September 2020 edition. This article is for informational purposes, is not intended to constitute legal advice, and may be considered advertising under applicable state laws. This article is only the opinion of the authors and is not attributable to Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, or the firm’s clients.

Related Insights

Reception

2026 IPO Education Foundation Awards Dinner

December 15, 2026

Washington, DC

Conference

ChIPs Global Summit 2026

October 21-23, 2026

Los Angeles

Seminar

As Congress Intended: Restoring the ITC’s Statutory Function Through Funding Transparency and Substantive Reforms

October 1, 2026

Washington, DC

Articles

Updates on Export Controls Impacting AI & Advanced Computing

September 21, 2026

Virtual Seminar

2026 ACC SFBA IP Symposium

September 17, 2026

Virtual

At the PTAB Blog

The Proof Is in the Priority: Director Squires Addresses Antedating and Prior-Art Qualification

September 14, 2026

Articles

Beyond Hikma: Patent Prosecution Strategies  for Anticipating Skinny-Label Generics  in Pharmaceutical Patent Portfolios

September 2026

Conference

Georgia Life Sciences Summit 2026

August 25-26, 2026

Sandy Springs

Seminar

Cosmetic Technology Showcase: Industry Insights

August 23-27, 2026

Chicago

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP